Published in J Biol Chem on March 10, 2010
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria. Kidney Int (2011) 1.94
Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature (2013) 1.65
Wnt/β-catenin signaling and kidney fibrosis. Kidney Int Suppl (2011) (2014) 1.01
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood (2015) 0.97
WT1 and kidney progenitor cells. Organogenesis (2010) 0.97
The yin and yang of kidney development and Wilms' tumors. Genes Dev (2015) 0.95
β-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Am J Pathol (2011) 0.94
Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol (2015) 0.93
Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene. J Biol Chem (2014) 0.85
Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms' Tumor Gene, WT1. Front Mol Neurosci (2011) 0.85
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov (2016) 0.84
WT1 targets Gas1 to maintain nephron progenitor cells by modulating FGF signals. Development (2015) 0.82
CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia. Oncotarget (2013) 0.82
Discovery of novel vitamin D receptor interacting proteins that modulate 1,25-dihydroxyvitamin D3 signaling. J Steroid Biochem Mol Biol (2012) 0.80
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med (2015) 0.80
The 1918 Influenza Virus PB2 Protein Enhances Virulence through the Disruption of Inflammatory and Wnt-Mediated Signaling in Mice. J Virol (2015) 0.78
WT1 expression in the human fetus during development. Eur J Histochem (2015) 0.78
Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis. Gut (2015) 0.76
Length of paternal lifespan is manifested in the DNA methylome of their nonagenarian progeny. Oncotarget (2015) 0.76
A biomimetic gelatin-based platform elicits a pro-differentiation effect on podocytes through mechanotransduction. Sci Rep (2017) 0.76
Increased incidence of ectopic pregnancy after in vitro fertilization in women with decreased ovarian reserve. Oncotarget (2017) 0.75
Estradiol-Estrogen Receptor α Mediates the Expression of the CXXC5 Gene through the Estrogen Response Element-Dependent Signaling Pathway. Sci Rep (2016) 0.75
Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. J Exp Med (2017) 0.75
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol (2017) 0.75
Stages of embryonic development of the zebrafish. Dev Dyn (1995) 42.72
WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet (2004) 10.38
WT-1 is required for early kidney development. Cell (1993) 7.05
Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet (2005) 6.67
Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol (2003) 6.60
Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science (2007) 5.08
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium (2005) 3.46
Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A (1991) 2.83
Renal abnormalities and their developmental origin. Nat Rev Genet (2007) 2.79
Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene (2001) 2.63
Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. Cell (2001) 2.42
Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer (2005) 2.19
The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet (2006) 2.10
Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell (1998) 1.91
The Wilms tumor genes wt1a and wt1b control different steps during formation of the zebrafish pronephros. Dev Biol (2007) 1.91
Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res (2000) 1.82
CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol (2004) 1.72
WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet (2002) 1.70
Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer (2008) 1.62
Wt1 negatively regulates beta-catenin signaling during testis development. Development (2008) 1.61
Zebrafish wnt8 and wnt8b share a common activity but are involved in distinct developmental pathways. Development (1995) 1.56
Wilms tumor and the WT1 gene. Exp Cell Res (2001) 1.49
Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. Hum Mol Genet (2003) 1.44
Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein. Mol Cell Biol (2001) 1.36
An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci U S A (2009) 1.26
CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem (2008) 1.23
Transcriptional regulation by WT1 in development. Curr Opin Genet Dev (2005) 1.19
Interaction between the internal motif KTXXXI of Idax and mDvl PDZ domain. Biochem Biophys Res Commun (2004) 1.14
Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem (2007) 1.13
Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol (2006) 1.11
Identification and characterization of human CXXC10 gene in silico. Int J Oncol (2004) 1.02
Cancer. Converging on beta-catenin in Wilms tumor. Science (2007) 0.98
The wt1-heterozygous mouse; a model to study the development of glomerular sclerosis. J Pathol (2003) 0.94
Inhibition of breast cancer cell growth by the Wilms' tumor suppressor WT1 is associated with a destabilization of beta-catenin. Anticancer Res (2003) 0.91
Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer (2007) 0.80
[Wilms tumor gene (WT1) expression in blood cells from patients with myelodysplastic syndrome]. Vopr Onkol (2004) 0.77
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
Lysosomal glycosphingolipid recognition by NKT cells. Science (2004) 7.31
salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell (2002) 7.15
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science (2007) 4.00
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis. J Biol Chem (2004) 2.62
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Identification of adult nephron progenitors capable of kidney regeneration in zebrafish. Nature (2011) 2.42
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury. PLoS One (2013) 2.14
Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med (2009) 2.12
Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature (2010) 2.10
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology (2006) 2.05
Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J Gastroenterol Hepatol (2006) 2.04
Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol (2015) 2.02
Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med (2013) 1.98
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res (2005) 1.97
DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell (2003) 1.94
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer (2010) 1.92
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
The Wilms tumor genes wt1a and wt1b control different steps during formation of the zebrafish pronephros. Dev Biol (2007) 1.91
Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90
The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist (2010) 1.84
Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol (2004) 1.82
Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell (2002) 1.80
Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor. PLoS Genet (2009) 1.77
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. Biochem Biophys Res Commun (2003) 1.72
The Wnt antagonist Frzb-1 regulates chondrocyte maturation and long bone development during limb skeletogenesis. Dev Biol (2002) 1.68
Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir Ther (2011) 1.65
Stromal-epithelial crosstalk regulates kidney progenitor cell differentiation. Nat Cell Biol (2013) 1.64
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol (2012) 1.63
Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. Genes Dev (2005) 1.60
Homozygous inactivation of Sox9 causes complete XY sex reversal in mice. Biol Reprod (2005) 1.59
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A (2009) 1.57
Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology (2003) 1.56
Characterization of mesonephric development and regeneration using transgenic zebrafish. Am J Physiol Renal Physiol (2010) 1.55
Distinct domains of AU-rich elements exert different functions in mRNA destabilization and stabilization by p38 mitogen-activated protein kinase or HuR. Mol Cell Biol (2004) 1.52
Sustained low hepatitis B viral load predicts good outcome after curative resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2010) 1.51
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr Blood Cancer (2013) 1.46
Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol (2005) 1.46
S1P1 receptor directs the release of immature B cells from bone marrow into blood. J Exp Med (2010) 1.43
Can "healthy" normal alanine aminotransferase levels identify the metabolically obese phenotype? Findings from the Korea national health and nutrition examination survey 2008-2010. Dig Dis Sci (2014) 1.43
Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc Natl Acad Sci U S A (2005) 1.43
Uvrag targeting by Mir125a and Mir351 modulates autophagy associated with Ewsr1 deficiency. Autophagy (2015) 1.42
P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev (2003) 1.41
Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res (2006) 1.40
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer (2008) 1.40
[In vitro culture of hepatitis C virus (HCV) using immortalized hepatocyte]. Korean J Gastroenterol (2008) 1.39
Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest (2007) 1.39
The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1. Genes Dev (2002) 1.38
Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys (2010) 1.36
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell (2010) 1.34
Cited1 and Cited2 are differentially expressed in the developing kidney but are not required for nephrogenesis. Dev Dyn (2007) 1.34
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett (2011) 1.33
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
A blood-based test for epidermal growth factor receptor mutations in lung cancer. Clin Cancer Res (2006) 1.32
Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood (2002) 1.30
Identification and comparative expression analysis of a second wt1 gene in zebrafish. Dev Dyn (2006) 1.29
Mst1-FoxO signaling protects Naïve T lymphocytes from cellular oxidative stress in mice. PLoS One (2009) 1.28
Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev Biol (2011) 1.27
BRAF and KRAS mutations in stomach cancer. Oncogene (2003) 1.27
Genetic determination of nephrogenesis: the Pax/Eya/Six gene network. Pediatr Nephrol (2003) 1.27
Autolysosomal β-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J (2013) 1.26
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci (2008) 1.24
A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem (2004) 1.23
A highly conserved retinoic acid responsive element controls wt1a expression in the zebrafish pronephros. Development (2009) 1.23
Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res (2007) 1.22
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov (2013) 1.21
Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem (2010) 1.20
HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med (2005) 1.20